|Mr. David C. Marek||CEO & Director||1.43M||N/A||1965|
|Mr. Uneek Mehra||Principal Financial Officer||631.36k||N/A||1972|
|Ms. Lauren Merendino||Chief Commercial Officer||643.23k||N/A||1975|
|Mr. Matthew Lang J.D.||Gen. Counsel & Corp. Sec.||N/A||N/A||1976|
|Mr. Albert Liao||Director of Corp. Communications||N/A||N/A||N/A|
|Mr. Bryan Selby||Sr. VP of Product Devel.||N/A||N/A||N/A|
|Dr. Juan Camilo Arjona Ferreira M.D.||Chief Medical Officer||N/A||N/A||1970|
|Dr. Andria Langenberg M.D.||Head of Drug Safety & Pharmacovigilance||N/A||N/A||1957|
|Mr. Jeffrey D. Nornhold||Sr. VP of Pharmaceutical Operations & Devel.||N/A||N/A||1966|
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Myovant Sciences Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.